Skip to content
Prime Therapeutics, Main logo
  • Health plans
  • Employers
  • Consultants
  • Careers
  • Resources
    • Pharmacist
    • Client + Health Plan
Member Sign In
  • About
    • Overview
    • Our History
    • Culture
    • Our Leaders
  • Who We Serve
    • Health plans
    • Employers
    • Consultants
  • News
  • Products
  • Resources
    • Pharmacy
    • Client and health plan
  • Careers
    • Overview
    • Benefits
    • Open Positions
  • Contact
Member Sign In
Home/Client Communications/New ALS drug wins approval from the FDA 

New ALS drug wins approval from the FDA 

March 8, 2023

Relyvrio was approved by the Food and Drug Administration (FDA) following a clinical trial, making it the first new ALS treatment to receive approval since 2017.
Prime Therapeutics Logo

Navigate

  • About
  • Products
  • News
  • Resources
  • Careers
  • Contact

Other Websites

  • Magellan Rx
  • myprime.com

Legal

  • Privacy Policy
  • Terms of Use
  • Subrogation
Prime Therapeutics Logo

Stay Connected

NCQA Certified Health Information Product
HITrust CSF Certfied
AICPA SOC for Service Organizations certification

© 2023 Prime Therapeutics LLC | Magellan Rx Management, LLC, a Prime Therapeutics LLC company